Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Debt to Equity: 2017-2021

Historic Debt to Equity for Sunshine Biopharma (SBFM) over the last 4 years, with Dec 2021 value amounting to $8.98.

  • Sunshine Biopharma's Debt to Equity rose 1003.17% to $8.98 in Q4 2021 from the same period last year, while for Dec 2021 it was $34.23, marking a year-over-year increase of 3544.19%. This contributed to the annual value of $8.98 for FY2021, which is 1003.17% up from last year.
  • According to the latest figures from FY2021, Sunshine Biopharma's Debt to Equity is $8.98, which was up 1,003.17% from -$0.99 recorded in FY2020.
  • In the past 5 years, Sunshine Biopharma's Debt to Equity registered a high of $8.98 during FY2021, and its lowest value of -$5.57 during FY2018.
  • Moreover, its 2-year median value for Debt to Equity was $3.99 (2020), whereas its average is $3.99.
  • Per our database at Business Quant, Sunshine Biopharma's Debt to Equity plummeted by 3,908.81% in 2018 and then skyrocketed by 1,003.17% in 2021.
  • Sunshine Biopharma's Debt to Equity (Yearly) stood at -$0.14 in 2017, then slumped by 3,908.81% to -$5.57 in 2018, then reached -$0.99 in 2020, then spiked by 1,003.17% to $8.98 in 2021.